

Nicola J Mccarthy

List of Publications by Citations

Source: <https://exaly.com/author-pdf/952447/nicola-j-mccarthy-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

147
papers

540
citations

10
h-index

17
g-index

275
ext. papers

583
ext. citations

30.4
avg, IF

4.7
L-index

#	Paper	IF	Citations
147	Interferon-gamma induces Fas trafficking and sensitization to apoptosis in vascular smooth muscle cells via a PI3K- and Akt-dependent mechanism. <i>American Journal of Pathology</i> , 2006 , 168, 2054-63	5.8	74
146	Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance. <i>Scientific Reports</i> , 2017 , 7, 17693	4.9	29
145	Increasing the performance of pooled CRISPR-Cas9 drop-out screening. <i>Scientific Reports</i> , 2016 , 6, 31782	4.9	21
144	Tumorigenesis: All together now. <i>Nature Reviews Cancer</i> , 2013 , 13, 148	31.3	21
143	Metabolism: unmasking an oncometabolite. <i>Nature Reviews Cancer</i> , 2012 , 12, 229	31.3	18
142	Isolation of genes controlling apoptosis through their effects on cell survival. <i>Gene Therapy and Molecular Biology</i> , 2006 , 10, 255-262		18
141	Autophagy: Directed development. <i>Nature Reviews Cancer</i> , 2014 , 14, 74-5	31.3	17
140	Epigenetics. Going places with BANCR. <i>Nature Reviews Cancer</i> , 2012 , 12, 451	31.3	16
139	Retinoblastoma: Epigenetic outcome. <i>Nature Reviews Cancer</i> , 2012 , 12, 80	31.3	15
138	Cancer: Small losses, big gains with microRNAs. <i>Nature Reviews Genetics</i> , 2010 , 11, 8	30.1	10
137	Regulatory RNA: layer by layer. <i>Nature Reviews Genetics</i> , 2011 , 12, 804	30.1	9
136	Metastasis: Influencing bad behaviour. <i>Nature Reviews Cancer</i> , 2009 , 9, 609	31.3	9
135	Prognostic models: rising to the challenge. <i>Nature Reviews Cancer</i> , 2013 , 13, 378	31.3	8
134	Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines. <i>Metabolomics</i> , 2020 , 16, 51	4.7	7
133	Tumorigenesis: oncogene detox programme. <i>Nature Reviews Cancer</i> , 2011 , 11, 622-3	31.3	7
132	Leukaemia: MLL makes friends and influences. <i>Nature Reviews Cancer</i> , 2010 , 10, 529	31.3	7
131	Cell signalling: Regulation and crosstalk. <i>Nature Reviews Molecular Cell Biology</i> , 2010 , 11, 390	48.7	7

130	Bladder cancer: seemingly similar. <i>Nature Reviews Cancer</i> , 2014 , 14, 214-5	31.3	6
129	Tumour heterogeneity: the cancer kaleidoscope. <i>Nature Reviews Cancer</i> , 2014 , 14, 151-2	31.3	6
128	Cancer stem cells: Tracing clones. <i>Nature Reviews Cancer</i> , 2012 , 12, 579	31.3	6
127	Epigenetics: Worth another look?. <i>Nature Reviews Cancer</i> , 2011 , 12, 2	31.3	6
126	Leukaemia: Gimme shelter. <i>Nature Reviews Cancer</i> , 2013 , 13, 297	31.3	5
125	Therapeutics: turnover. <i>Nature Reviews Cancer</i> , 2013 , 13, 380-1	31.3	5
124	Signalling: Regulation and crosstalk. <i>Nature Reviews Cancer</i> , 2010 , 10, 386	31.3	5
123	Inflammation: An innate response. <i>Nature Reviews Cancer</i> , 2015 , 15, 197	31.3	4
122	Breast cancer: Hypoxia and XBP1S. <i>Nature Reviews Cancer</i> , 2014 , 14, 295	31.3	4
121	Metastasis: understanding the prowess of mutant p53. <i>Nature Reviews Cancer</i> , 2014 , 14, 385	31.3	4
120	Leukaemia: Knowing left from right. <i>Nature Reviews Cancer</i> , 2013 , 13, 220-1	31.3	4
119	Retroviral insertional mutagenesis implicates E3 ubiquitin ligase RNF168 in the control of cell proliferation and survival. <i>Bioscience Reports</i> , 2017 , 37,	4.1	4
118	Tumour suppressors: Master weaver regulates guardian. <i>Nature Reviews Cancer</i> , 2014 , 14, 295	31.3	4
117	Migration: VEGF suppresses invasion. <i>Nature Reviews Cancer</i> , 2012 , 12, 581	31.3	4
116	Tumour heterogeneity: Darwin's finches. <i>Nature Reviews Cancer</i> , 2012 , 12, 317	31.3	4
115	Signalling: SRC and survival. <i>Nature Reviews Cancer</i> , 2012 , 12, 80-1	31.3	4
114	Leaky effect. <i>Nature Reviews Cancer</i> , 2012 , 12, 157	31.3	4
113	Metabolism: a TIGAR tale. <i>Nature Reviews Cancer</i> , 2013 , 13, 522	31.3	4

112	Signalling: REX rules. <i>Nature Reviews Cancer</i> , 2011 , 11, 83	31.3	4
111	Prostate cancer: Studying the classics. <i>Nature Reviews Cancer</i> , 2011 , 11, 386	31.3	4
110	Metastasis: Twisting BMI1. <i>Nature Reviews Cancer</i> , 2010 , 10, 666	31.3	4
109	Tumour microenvironment: losing your SPARC. <i>Nature Reviews Cancer</i> , 2014 , 14, 10-1	31.3	3
108	Anticancer drugs: Targeting menin. <i>Nature Reviews Drug Discovery</i> , 2012 , 11, 190	64.1	3
107	Signalling: YAP, PTEN and miR-29 size each other up. <i>Nature Reviews Cancer</i> , 2013 , 13, 4-5	31.3	3
106	MicroRNA: lacking in maturity. <i>Nature Reviews Cancer</i> , 2013 , 13, 377	31.3	3
105	Therapeutics: targeting an oncometabolite. <i>Nature Reviews Cancer</i> , 2013 , 13, 383	31.3	3
104	Heterogeneity: A multidimensional overview. <i>Nature Reviews Cancer</i> , 2013 , 13, 439	31.3	3
103	Tumour microenvironment: target practice. <i>Nature Reviews Cancer</i> , 2011 , 11, 315	31.3	3
102	Systems biology: Lethal weaknesses. <i>Nature Reviews Cancer</i> , 2011 , 11, 538-9	31.3	3
101	Tumour suppressors: HOTS makes antisense. <i>Nature Reviews Cancer</i> , 2011 , 11, 758	31.3	3
100	Cell polarity: ASPP2 gets a polarity complex. <i>Nature Reviews Cancer</i> , 2010 , 10, 528	31.3	3
99	Finding your inner activator. <i>Nature Reviews Cancer</i> , 2010 , 10, 812	31.3	3
98	Metastasis: Route master. <i>Nature Reviews Cancer</i> , 2009 , 9, 610	31.3	3
97	Metastasis: SIX1 of the best. <i>Nature Reviews Cancer</i> , 2012 , 12, 316	31.3	3
96	Tumorigenesis: Cut here for differentiation. <i>Nature Reviews Cancer</i> , 2012 , 12, 320	31.3	3
95	Tumorigenesis: Megaphone MYC. <i>Nature Reviews Cancer</i> , 2012 , 12, 733	31.3	3

94	Metabolism: Mutant BRAF feels the burn. <i>Nature Reviews Cancer</i> , 2015 , 15, 454-5	31.3	2
93	Drug resistance: making a point. <i>Nature Reviews Cancer</i> , 2014 , 14, 6	31.3	2
92	Cachexia: running on empty. <i>Nature Reviews Cancer</i> , 2014 , 14, 576	31.3	2
91	Hypoxia: micro changes. <i>Nature Reviews Cancer</i> , 2014 , 14, 382-3	31.3	2
90	Epigenetics: Showing a more sensitive side. <i>Nature Reviews Cancer</i> , 2013 , 13, 680	31.3	2
89	Epigenetics: the long view. <i>Nature Reviews Cancer</i> , 2013 , 13, 76	31.3	2
88	Lung cancer: A surprising competitor. <i>Nature Reviews Cancer</i> , 2014 , 14, 73	31.3	2
87	Rhabdomyosarcoma: flexibility could be important. <i>Nature Reviews Cancer</i> , 2014 , 14, 156-7	31.3	2
86	Cell death. 1+1=2. <i>Nature Reviews Cancer</i> , 2012 , 12, 449	31.3	2
85	Cell cycle: a WEE pointer. <i>Nature Reviews Cancer</i> , 2012 , 12, 378-9	31.3	2
84	Enforced compliance. <i>Nature Reviews Cancer</i> , 2012 , 12, 152	31.3	2
83	Metabolism: Sensitivity to serine starvation. <i>Nature Reviews Cancer</i> , 2013 , 13, 77	31.3	2
82	Tumour suppressors: Selective justice. <i>Nature Reviews Cancer</i> , 2011 , 11, 4	31.3	2
81	Autophagy: limiting factors. <i>Nature Reviews Cancer</i> , 2011 , 11, 313	31.3	2
80	That's the theory. <i>Nature Reviews Cancer</i> , 2011 , 11, 691	31.3	2
79	Leukaemia: Adding e for survival. <i>Nature Reviews Cancer</i> , 2012 , 12, 230	31.3	2
78	Tumorigenesis. Better by half. <i>Nature Reviews Cancer</i> , 2012 , 12, 450-1	31.3	2
77	Pancreatic cancer: spotlight on BRG1. <i>Nature Reviews Cancer</i> , 2014 , 14, 213	31.3	1

76	Chromatin remodelling: looking vulnerable. <i>Nature Reviews Cancer</i> , 2014 , 14, 217	31.3	1
75	Epigenetics: prognosis based on commitment signature. <i>Nature Reviews Cancer</i> , 2014 , 14, 153	31.3	1
74	Tumorigenesis: WNT branches out. <i>Nature Reviews Cancer</i> , 2013 , 13, 80	31.3	1
73	Metastasis: ADORA(2B)tion. <i>Nature Reviews Cancer</i> , 2013 , 13, 294-5	31.3	1
72	Glioblastoma: The histones have it. <i>Nature Reviews Cancer</i> , 2013 , 13, 294	31.3	1
71	Stem cells: As directed. <i>Nature Reviews Cancer</i> , 2013 , 13, 824	31.3	1
70	Ubiquitylation: Mediation by degradation. <i>Nature Reviews Cancer</i> , 2013 , 13, 146	31.3	1
69	Melanoma: Horses for courses. <i>Nature Reviews Cancer</i> , 2013 , 13, 222	31.3	1
68	Immunotherapy: Put your coat on!. <i>Nature Reviews Cancer</i> , 2015 , 15, 319	31.3	1
67	Tumour microenvironment: more than just a mutagen. <i>Nature Reviews Cancer</i> , 2014 , 14, 213	31.3	1
66	Mitochondria: Getting together. <i>Nature Reviews Cancer</i> , 2012 , 12, 661	31.3	1
65	Immunotherapy: Adapt and survive. <i>Nature Reviews Cancer</i> , 2012 , 12, 738-9	31.3	1
64	Mitochondria: getting together. <i>Nature Reviews Molecular Cell Biology</i> , 2012 , 13, 604-5	48.7	1
63	Catching the X-waves. <i>Nature Reviews Cancer</i> , 2012 , 12, 510	31.3	1
62	Genes, genes everywhere. <i>Nature Reviews Cancer</i> , 2012 , 12, 507	31.3	1
61	Breast cancer: Staking a claim. <i>Nature Reviews Cancer</i> , 2011 , 12, 4	31.3	1
60	Lung cancer: Gastric giveaways. <i>Nature Reviews Cancer</i> , 2013 , 13, 291	31.3	1
59	Glioblastoma: histone mutations take the MYCN. <i>Nature Reviews Cancer</i> , 2013 , 13, 382-3	31.3	1

58	Epigenetics. Layer by layer. <i>Nature Reviews Cancer</i> , 2011 , 11, 830	31.3	1
57	Nanotechnology: Tag teams. <i>Nature Reviews Cancer</i> , 2011 , 11, 537	31.3	1
56	Tumour suppressors: Silencing heterochromatin. <i>Nature Reviews Cancer</i> , 2011 , 11, 760	31.3	1
55	Pushing on through. <i>Nature Reviews Cancer</i> , 2010 , 10, 452	31.3	1
54	The ARTS of cell death. <i>Nature Reviews Cancer</i> , 2010 , 10, 816	31.3	1
53	Tumorigenesis: Replicating recurrence. <i>Nature Reviews Cancer</i> , 2009 , 9, 613	31.3	1
52	Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines. <i>Metabolomics</i> , 2021 , 17, 104	4.7	1
51	Prostate cancer: understanding why. <i>Nature Reviews Cancer</i> , 2013 , 13, 754	31.3	0
50	Systems biology: MoA on DeMAND. <i>Nature Reviews Genetics</i> , 2015 , 16, 498-9	30.1	
49	Metabolism: Feed a cold, starve a tumour. <i>Nature Reviews Cancer</i> , 2015 , 15, 4-5	31.3	
48	Bladder cancer: finding the origin. <i>Nature Reviews Cancer</i> , 2014 , 14, 386-7	31.3	
47	Therapeutics: Embracing instability. <i>Nature Reviews Cancer</i> , 2013 , 13, 521	31.3	
46	Metabolism: How sweet it is.... <i>Nature Reviews Cancer</i> , 2013 , 13, 605	31.3	
45	Metastasis: Going places with VHL. <i>Nature Reviews Cancer</i> , 2013 , 13, 78	31.3	
44	Polarity: In the plane. <i>Nature Reviews Cancer</i> , 2013 , 13, 606-7	31.3	
43	DNA damage: Running in parallel. <i>Nature Reviews Cancer</i> , 2013 , 13, 679	31.3	
42	Epigenetics: WIP1 creates hush and havoc. <i>Nature Reviews Cancer</i> , 2013 , 13, 822	31.3	
41	Metabolism: Nuclear or cytoplasmic?. <i>Nature Reviews Cancer</i> , 2013 , 13, 822	31.3	

40	Signalling: Keeping TABs on p53. <i>Nature Reviews Cancer</i> , 2013 , 13, 682	31.3
39	Therapeutics: Disrupting a survival signal. <i>Nature Reviews Cancer</i> , 2013 , 13, 608-9	31.3
38	Drug resistance: Time for mediation?. <i>Nature Reviews Cancer</i> , 2013 , 13, 6-7	31.3
37	DNA damage: In at the beginning. <i>Nature Reviews Cancer</i> , 2013 , 13, 147	31.3
36	Metastasis: Elf represses snail. <i>Nature Reviews Cancer</i> , 2012 , 12, 795	31.3
35	Lung cancer: radial targets. <i>Nature Reviews Cancer</i> , 2012 , 12, 373	31.3
34	The great pretenders. <i>Nature Reviews Cancer</i> , 2012 , 12, 506	31.3
33	Metastasis: No sympathy?. <i>Nature Reviews Cancer</i> , 2012 , 12, 584-5	31.3
32	Immunotherapy: Unlicensed to kill. <i>Nature Reviews Immunology</i> , 2012 , 12, 682-3	36.5
31	Proliferation: Multitasking. <i>Nature Reviews Cancer</i> , 2012 , 12, 660-1	31.3
30	Breast cancer: divide and conquer?. <i>Nature Reviews Cancer</i> , 2012 , 12, 375	31.3
29	Targeting menin. <i>Nature Reviews Cancer</i> , 2012 , 12, 154	31.3
28	Melanoma: More horses. <i>Nature Reviews Cancer</i> , 2013 , 13, 296-7	31.3
27	Cell death: A2B via p53. <i>Nature Reviews Cancer</i> , 2013 , 13, 440-1	31.3
26	Leukaemia: Holding back. <i>Nature Reviews Cancer</i> , 2013 , 13, 224-5	31.3
25	Stem cells: Self-sufficient. <i>Nature Reviews Cancer</i> , 2011 , 11, 6	31.3
24	Medulloblastoma: origins. <i>Nature Reviews Cancer</i> , 2011 , 11, 80	31.3
23	Immunology: bad company. <i>Nature Reviews Cancer</i> , 2011 , 11, 311	31.3

22	Leukaemia: Now get out of that. <i>Nature Reviews Cancer</i> , 2011 , 11, 388	31.3
21	Tumour suppression: Shedding light on degradation. <i>Nature Reviews Cancer</i> , 2011 , 11, 466	31.3
20	Chromosomal instability: a lack of new origins drives fragility. <i>Nature Reviews Cancer</i> , 2011 , 11, 626-7	31.3
19	Haem is where the heart is. <i>Nature Reviews Cancer</i> , 2011 , 11, 692	31.3
18	Kidney tumours. SNRF said. <i>Nature Reviews Cancer</i> , 2011 , 11, 833	31.3
17	Anticancer drugs: Now get out of that. <i>Nature Reviews Drug Discovery</i> , 2011 , 10, 414-5	64.1
16	Tumour immunology: Early exposure is inflammatory. <i>Nature Reviews Immunology</i> , 2011 , 11, 157	36.5
15	Tumour immunology: bad company. <i>Nature Reviews Immunology</i> , 2011 , 11, 303	36.5
14	Neuroendocrinology: Housing conditions affect tumour growth. <i>Nature Reviews Neuroscience</i> , 2010 , 11, 613	13.5
13	Tumour suppression: Double act. <i>Nature Reviews Cancer</i> , 2010 , 10, 382	31.3
12	DNA damage: "Curiouser and curiouser!" cried Alice. <i>Nature Reviews Cancer</i> , 2010 , 10, 532-3	31.3
11	Genomics: A broad brush. <i>Nature Reviews Cancer</i> , 2010 , 10, 600	31.3
10	Immunology: In need of a boost?. <i>Nature Reviews Cancer</i> , 2010 , 10, 742	31.3
9	Tumour suppression: Ejector seat. <i>Nature Reviews Cancer</i> , 2010 , 10, 739	31.3
8	Stem cells: Out for the count. <i>Nature Reviews Cancer</i> , 2010 , 10, 742	31.3
7	Anticancer drugs: RAF complexities spark caution. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 271	64.1
6	Genomics: Viral vista. <i>Nature Reviews Cancer</i> , 2012 , 12, 582	31.3
5	Towards a mechanism. <i>Nature Reviews Cancer</i> , 2012 , 12, 510-1	31.3

- 4 Leukaemia: Early changes. *Nature Reviews Cancer*, **2012**, 12, 799 31.3
- 3 Immunotherapy: Unlicensed to kill. *Nature Reviews Cancer*, **2012**, 12, 658-9 31.3
- 2 DNA damage: The enemy within. *Nature Reviews Cancer*, **2012**, 12, 734 31.3
- 1 Tumorigenesis: Influencing those around you. *Nature Reviews Cancer*, **2012**, 12, 734 31.3